Influence of bilateral oophorectomy upon lipid metabolism

Maturitas

Volumn 29, Issue 2, 1998, Pages 147-154

  Suda, Yoshio ^a   Ohta, Hiroaki ^a   Makita, Kazuya ^a   Takamatsu, Kiyoshi ^a   Horiguchi, Fumi ^a   Nozawa, Shiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Apoprotein B; Arteriosclerosis; LDL cholesterol; Oophorectomy; Total cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY RISK; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARIECTOMY;

APOPROTEINS; ARTERIOSCLEROSIS; CHOLESTEROL; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEIN(A); LIPOPROTEINS; MIDDLE AGED; OVARIECTOMY; TRIGLYCERIDES;

EID: 0032479024     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00089-3     Document Type: Article

References (31)

1. The Research Committee of Primary Hyperlipidemia. Annual Report of Primary Hyperlipidemia. Ministry of Health and Welfare, Japan, 1995 (in Japanese).
2. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 74:1971;1-12.
3. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet. 2:1986;933-936.
4. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc. 251:1984;351-364.
5. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjöblom T., Nikkilä E.A. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl J Med. 317:1987;1237-1245.
6. The Pravastatin Multinaitonal Study Group for Cardiac Risk patients Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 72:1993;1031-1037.
7. Pitt B., Ellis S.G., Mancini G.B.J., Rosman H.S., McGovern M.E. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol. 72:1993;31-35.
8. Furberg C.D., Byington R.P., Crouse J.R., Espeland M.A. Pravastatin, lipids, and major coronary events. Am J Cardiol. 73:1994;1133-1134.
9. MAAS Investigators Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet. 344:1994;633-638.
10. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
11. Waters D., Higginson L., Gladstone P., Limbell B., Le May M., Bocuzzi S.J., Lespérance J. Effects of monotherapy with and HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
12. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
13. Sekimoto H., Goto Y., Goto Y., Naitoh C., Yasugi T., Okido M., Kuzuya F., Takeda R., Yamamoto A., Fukuzaki H., Kajiyama G., Kokubo T., Uzawa H., Mimura G., Shimada O. Changes of serum total cholesterol and triglyceride levels in normal subjects in Japan in the past twenty years. Research committee on familial hyperlipidemia in Japan. Jpn Circ J. 47:1983;1351-1358.
14. Lipid Research Clinics of Laboratory Operations. DHEW Publication No. (NIH) 85-268, 1975.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
16. Craig W.Y., Poulin S.E., Forster N.R., Neveux L.M., Wald N.J., Ledue T.B. Effect of sample storage on the assay of Lp(a) by commercially availlable radial immunodiffusion and enzyme-linked sorbent assay kits. Clin Chem. 38:1992;550-553.
17. Ishibashi S. Lipoprotein lipase. Nippon Rinsho 1989; 47: 550-552 (in Japanese).
18. The Pooling Project Research Group Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: Final Report of the Pooling Project. J Chron Dis. 31:1978;201-306.
19. The Research Committee of Primary Hyperlipidemia. Annual Report of Primary Hyperlipidemia. Ministry of Health and Welfare, Japan, 1987 (in Japanese).
20. Hayashi R., Kogure S., Sakaibori K., Kurihara S., Kasagi J., Murata K. Serum cholesterol level in normal people association of serum cholesterol level with age and relative body weight. Jpn J Med. 26:1987;153-157.
21. Mizunuma H, Honjo S, Soda M, Matsui H, Okano H, Igarashi M. Estrogen and heart diseases. Sanfujinka No Sekai 1990;42: 1079-1086 (in Japanese).
22. Ohta H, Suda Y, Makita K, Ikeda T, Masuzawa T, Komukai S, Nozawa S. Menopause and lipid-lipoprotein metabolism. J Jpn Menopause Soc 1993;1:80-85 (in Japanese with English abstract).
23. Berg K. A new serum type system in man- the Lp system. Acta Pathol Microbiol Scand. 59:1963;369-382.
24. Armstrong V.W., Cremer P., Eberle E., Manke A., Schulze F., Wieland H., Kreuzer H., Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 62:1986;249-257.
25. Ridker P.M., Hennekens C.H., Stampfer M.J. A prospective study of lipoprotein (a) and the risk of myocardial infarction. J Am Med Assoc. 270:1993;2195-2199.
26. 2+, and an anion-exchange resin. Clin Chem. 24:1978;1504-1508.
27. The Expert Panel Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 148:1988;36-69.
28. National Institutes of Health Consensus Development Conference on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease, February 1992.
29. Shiomi M., Ito T., Watanabe Y. Increase in hepatic low-density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipidemic rabbits; an animal model for familial hypercholesterolemia. Biochim Biophys Acta. 917:1987;92-100.
30. Mabuchi H., Sakai Y., Watanabe A., Haba T., Koizumi J., Takeda R. Normalization of low-density lipoprotein levels and disappearance of xanthomas during pregnancy in a woman with heterozygous familial hypercholesterolemia. Metabolism. 34:1985;309-315.
31. Honjo H., Tanaka K., Urabe M., Naitoh K., Ogino Y., Yamamoto T., Okada H. Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogen. Clin Ther. 14:1992;699-707.